SLGL
SLGL
NASDAQ · Pharmaceuticals

Sol-Gel Technologies Ltd

$76.02
+4.76 (+6.68%)
Financial Highlights (FY 2026)
Revenue
24.19M
Net Income
-7,645,380
Gross Margin
Profit Margin
-31.6%
Rev Growth
+71.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 29.4% 29.4%
Operating Margin -38.9% -35.0% 42.3% 41.5%
Profit Margin -31.6% -30.0% 33.8% 28.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 24.19M 14.15M 80.43M 74.82M
Gross Profit 23.62M 21.97M
Operating Income -9,406,167 -4,951,772 34.02M 31.02M
Net Income -7,645,380 -4,024,825 27.17M 21.09M
Gross Margin 29.4% 29.4%
Operating Margin -38.9% -35.0% 42.3% 41.5%
Profit Margin -31.6% -30.0% 33.8% 28.2%
Rev Growth +71.0% +71.0% -4.6% -5.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 45.73M 50.34M
Total Equity 128.24M 118.27M
D/E Ratio 0.36 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -9,270,193 -5,151,312 38.14M 36.98M
Free Cash Flow 15.33M 13.15M